Alnylam Pharmaceuticals: Piper Sandler cuts target price to $410 from $489
ALNY•Piper Sandler cut its target price for Alnylam Pharmaceuticals to $410 from $489.
Related News
Welltower Inc.: Raymond James cuts target price to $263 from $270
WELL•
Guggenheim raises Merck target price to $171 from $170
MRK•
JPMorgan raises Merit Medical Systems target price to $110 from $95
MMSI•
ResMed target price raised to $260 from $225
RMD•
Hershey: JP Morgan cuts target price to $166 from $183
HSY•